Immune Checkpoint Inhibitors: A New Hope for Cancer Patients

Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market (2^nd edition), 2015-2025” report to its portfolio. The study provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of Immune Checkpoint Inhibitors (ICIs).

Rupali Verma, the principal analyst, said, “The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were pioneers in this segment. Yervoy was the only immunotherapeutic commercially available until other classes stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost. In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which are expected to gain traction in the future.”

Verma further stated, “The market is currently characterized by the presence of three marketed drugs and 34 drugs in clinical development.

• BMS, with ten ICIs, is the leading player followed by other giants including AstraZeneca, Merck, Pfizer, Roche, GSK, Novartis and Amgen.
• Several molecules are being tested in combination with other drug classes; Jan 2014-May 2015 saw over 40 such collaborations.”

Amongst other things, the report covers:

• Current market outlook, along with key drivers and restraints, likely to influence future growth.
• Detailed analysis of the active/planned clinical studies evaluating phase II/III/marketed ICIs.
• Partnering activities which are likely to unfold as the market matures.
• Investments and grants received by companies focused in this area.
• Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.

In addition to the initiatives taken by the bigger firms, the report covers many start-ups and small companies which have also emerged. Examples include

• Agenus
• Alligator Bioscience
• Ambrx
• AnaptysBio
• arGEN-X
• Bioceros
• BioNovion
• Cellerant Therapeutics
• Checkpoint Therapeutics
• Compugen
• CureTech
• Enumeral
• Five Prime Therapeutics
• Genmab
• GITR
• ImmuNext
• IOmet Pharma
• iTeos Therapeutics
• Jounce Therapeutics
• KAHR Medical
• Multimeric Biotherapeutics
• Nativis
• Orega Biotech
• Pelican Therapeutics
• Pieris Pharmaceuticals
• Prima BioMed
• Redx Pharma
• Tesaro
• TG Therapeutics
• Theravectys
• ToleroTech

 For additional details, please visit https://www.rootsanalysis.com/reports/immune-checkpoint-inhibitors-market-2nd-edition-2015-2025/101.html or email sales@rootsanalysis.com

About Roots Analysis

Roots Analysis is a global life sciences market research, competitive intelligence, and strategic consulting firm specializing in the pharmaceutical, biotechnology, medical devices and healthcare industries. Founded in 2013, we have served 1,500+ global clients, from startups to Fortune 500 companies, helping them evaluate market opportunities, assess competition, and make data-driven business decisions. We also provide dedicated solutions to academic institutes, universities, non-profit organizations and other non-industry players.